Actively Recruiting

Early Phase 1
Age: 18Years - 75Years
All Genders
ID07295262

ICG-Cisplatin Self-Assembled Nanoprobes for Near-Infrared-II Fluorescence Imaging-Guided Liver Resection

Led by West China Hospital · Updated on 2025-12-19

30

Participants Needed

1

Research Sites

21 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating a new method to guide surgery for patients with Hepatocellular Carcinoma (HCC), a type of liver cancer. This early-phase study focuses on the safety and feasibility of using a novel nanoprobe made from Indocyanine Green and Cisplatin, called NIR-II NanoM, to help surgeons see tumor boundaries more clearly during operation. The goal is to improve precision in liver cancer surgery and study how well this imaging technique works. Participants will receive an injection of the nanoprobe mixed with lipiodol directly into the liver artery before surgery. After this, patients will undergo laparoscopic anatomic hepatectomy, where surgeons use a Near-Infrared II (NIR-II) fluorescence imaging system to visualize tumor edges and liver segments for a more precise removal. This single-arm study involves this one experimental treatment approach. During the study, patients will be closely monitored before, during, and after surgery. Researchers will measure how effectively the nanoprobe stains the tumor during surgery and track patients for up to three years to observe recurrence-free survival. They will also assess overall survival, adverse events, complications, and rates of local recurrence or distant metastasis. Follow-up includes regular imaging and health assessments to ensure safety and track long-term outcomes.

CONDITIONS

Brief Title

NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 75 years
  • First diagnosis of Hepatocellular Carcinoma (HCC), no recurrence
  • Single tumor with diameter 5 cm or less
  • Tumor assessed as resectable by more than two senior liver surgeons with extensive experience
  • No distant metastasis on chest CT and abdominal contrast-enhanced CT before surgery
  • Child-Pugh Class A liver function
  • Patient or legal guardian able to understand the study and provide informed consent
Not Eligible

You will not qualify if you...

  • Postoperative pathology confirming cholangiocarcinoma, sarcomatoid HCC, combined HCC-ICC, or fibrolamellar carcinoma
  • Presence of tumor thrombus in portal vein, hepatic vein, or bile duct
  • History of other malignancies except cured carcinoma in situ of cervix, basal cell carcinoma, or squamous cell skin carcinoma
  • Evidence of residual lesion, recurrence, or metastasis before surgery or positive lymph nodes or margins after surgery
  • Moderate to severe ascites requiring treatment or Child-Pugh score above 7 (except small asymptomatic ascites)
  • Uncontrolled or moderate/large pleural or pericardial effusion
  • Severe heart, lung, or kidney dysfunction
  • Ruptured HCC requiring emergency surgery
  • Patient or family unable to understand study conditions and goals

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 1 week

Participants receive transarterial embolization with ICG-Cisplatin nanoprobes for tumor staining, followed by fluorescence-guided laparoscopic anatomic hepatectomy.

1 treatment visit and surgery day

Follow-up

Duration - Up to 5 years post-surgery

Participants are monitored for recurrence, survival, and any perioperative adverse events for up to 3 to 5 years after surgery.

Periodic follow-up visits for up to 5 years

Trial Site Locations

Total: 1 location

1

West China Hospital

Chengdu, Sichuan, China, 610041

Actively Recruiting

Loading map...

Research Team

J

Jiwei Huang Professor

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

An Innovative CFD-based Dosimetry and Pre-treatment Planning...

Hepatocellular Carcinoma (HCC)

Actively Recruiting

1 location

Development of 3D Multi-Parametric Ultrasound (MPUS) as a De...

Liver Cancer, Adult

Actively Recruiting

3 locations

Digital Intelligence Early Warning System for Acute Lung Inj...

Acute Lung Injury(ALI)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here